Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients | Zendy

Juan José Castón | Zendy; Isabel Lacort-Peralta | Zendy; Pilar MartínDávila | Zendy; Belén Loeches | Zendy; Salvador Tabares | Zendy; Liz Temkin | Zendy; Julián TorreCisneros | Zendy; José Ramón PañoPardo | Zendy

Open Access

Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients

Author(s) -

Juan José Castón,

Isabel Lacort-Peralta,

Pilar MartínDávila,

Belén Loeches,

Salvador Tabares,

Liz Temkin,

Julián TorreCisneros,

José Ramón PañoPardo

Publication year - 2017

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2017.03.021

Subject(s) - bacteremia , medicine , ceftazidime/avibactam , septic shock , ceftazidime , retrospective cohort study , avibactam , mortality rate , surgery , sepsis , antibiotics , microbiology and biotechnology , pseudomonas aeruginosa , biology , genetics , bacteria

The primary objective was to describe clinical features, treatment and outcomes in patients with carbapenemase-producing Enterobacteriaceae (CPE) bacteremia. Additionally, patients treated with ceftazidime/avibactam (study group) were compared to the rest of the patients (comparator group) to determine the influence of the treatment in both crude mortality and clinical cure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research